NMR Stock Analysis: Nomura Holdings | NYSE
Capital Markets | NYSE, USA | Market Cap: 28.583m USD | 12M Return: 42.3% | US65535H2085 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.60M
EPS Trend: -0.1%
Qual. Beats: 0
Rev. Trend: 76.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Nomura Holdings, Inc. (NYSE: NMR) is a Japan-headquartered global financial services group that provides investment, financing, and related services to individual, institutional, and government clients. Founded in 1925 and listed on the NYSE since 1961, Nomura operates as one of Japans largest brokerage and investment banking firms, with a large-cap market presence of approximately $28.96 billion USD. The company is classified within the Financials sector, specifically the Investment Banking & Brokerage sub-industry.
Nomura organizes its business into three core segments: Wealth Management, which delivers asset management services to retail and individual clients; Investment Management, which provides investment solutions, including the management of investment trusts, discretionary investment services, and funds for institutional investors; and Wholesale, which encompasses sales and trading of debt and equity securities, foreign exchange, and investment banking activities such as underwriting, M&A advisory, and financial advisory services. The Wholesale segment is central to its global institutional and capital markets franchise, while the Investment Management arm connects Nomura to the broader asset and fund management industry.
- BoJ rate hikes boost wealth management net interest income
- Wholesale investment banking revenue surges on M&A recovery
- Asset management AUM declines on Japanese equity market weakness
| Net Income: 403b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA -0.26 > 1.0 |
| NWC/Revenue: -46.82% < 20% (prev 300.8%; Δ -347.6% < -1%) |
| CFO/TA -0.01 > 3% & CFO -843b > Net Income 403b |
| Net Debt (339b) to EBITDA (1367b): 0.25 < 3 |
| Current Ratio: 0.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.01b) vs 12m ago -1.97% < -2% |
| Gross Margin: 53.11% > 18% (prev 38.90%; Δ 14.21% > 0.5%) |
| Asset Turnover: 6.86% > 50% (prev 7.65%; Δ -0.78% > 0%) |
| Interest Coverage Ratio: 0.47 > 6 (EBIT TTM 1242b / Interest Expense TTM 2642b) |
| A: -0.03 (Total Current Assets 40755b - Total Current Liabilities 42784b) / Total Assets 68224b |
| B: 0.03 (Retained Earnings 2152b / Total Assets 68224b) |
| C: 0.02 (EBIT TTM 1242b / Avg Total Assets 63163b) |
| D: 0.06 (Book Value of Equity 3834b / Total Liabilities 64230b) |
| Altman-Z'' = 0.10 = B |
| DSRI: 1.25 (Receivables 5758b/4727b, Revenue 4333b/4442b) |
| GMI: 0.73 (GM 38.90% / 53.11%) |
| AQI: 2.36 (AQ_t 0.39 / AQ_t-1 0.17) |
| SGI: 0.98 (Revenue 4333b / 4442b) |
| TATA: 0.02 (NI 403b - CFO -843b) / TA 68224b) |
| Beneish M = -2.27 (Cap -4..+1) = BBB |
As of October 14, 2026, the stock is trading at USD 9.58 with a total of 686,801 shares traded. Over the past week, the price has changed by -2.04%, over one month by -10.72%, over three months by -0.42% and over the past year by +42.29%.
Current recommended Stop Loss: 9.30 (which is 2.9% or 1.4 ATR below the current price).
Nomura Holdings has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy NMR.
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 11.2 | 17.1% |
Market Cap JPY = 4528b (28.6b USD * 158.41 USD.JPY)
P/E Trailing = 11.3721
P/E Forward = 15.3846
P/S = 0.0123
P/B = 1.1804
P/EG = 0.8146
Revenue TTM = 4333b JPY
EBIT TTM = 1242b JPY
EBITDA TTM = 1367b JPY
Long Term Debt = 17138b JPY (from longTermDebt, last quarter)
Short Term Debt = 18042b JPY (from shortTermDebt, last quarter)
Debt = 35336b JPY (from shortLongTermDebtTotal, last quarter) + Leases 156b
Net Debt = 339b JPY (calculated: Debt 35336b - CCE 34997b)
Enterprise Value = 4867b JPY (4528b + Debt 35336b - CCE 34997b)
Interest Coverage Ratio = 0.47 (Ebit TTM 1242b / Interest Expense TTM 2642b)
EV/FCF = -4.07x (Enterprise Value 4867b / FCF TTM -1197b)
FCF Yield = -24.59% (FCF TTM -1197b / Enterprise Value 4867b)
FCF Margin = -27.62% (FCF TTM -1197b / Revenue TTM 4333b)
Net Margin = 9.30% (Net Income TTM 403b / Revenue TTM 4333b)
Gross Margin = 53.11% ((Revenue TTM 4333b - Cost of Revenue TTM 2032b) / Revenue TTM)
Gross Margin QoQ = 89.18% (prev 53.22%)
Tobins Q-Ratio = 0.07 (Enterprise Value 4867b / Total Assets 68224b)
Interest Expense / Debt = 7.48% (Interest Expense 2642b / Debt 35336b)
Taxrate = 28.43% (168b / 591b)
NOPAT = 889b (EBIT 1242b * (1 - 28.43%))
Current Ratio = 0.95 (Total Current Assets 40755b / Total Current Liabilities 42784b)
Debt / Equity = 9.22 (Debt 35336b / totalStockholderEquity, last quarter 3834b)
Debt / EBITDA = 0.25 (Net Debt 339b / EBITDA 1367b)
Debt / FCF = -0.28 (negative FCF - burning cash) (Net Debt 339b / FCF TTM -1197b)
Total Stockholder Equity = 3670b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.64% (Net Income 403b / Total Assets 68224b)
RoE = 10.98% (Net Income TTM 403b / Total Stockholder Equity 3670b)
RoCE = 5.97% (EBIT 1242b / Capital Employed (Equity 3670b + L.T.Debt 17138b))
RoIC = 2.05% (NOPAT 889b / Invested Capital 43266b)
WACC = 5.87% (E(4528b)/V(39864b) * Re(9.88%) + D(35336b)/V(39864b) * Rd(7.48%) * (1-Tc(0.28)))
Discount Rate = 9.88% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -81.43 | Cagr: -1.94%
[DCF] Fair Price = unknown (Cash Flow -1197b)
EPS Correlation: -0.06 | EPS CAGR: -0.13% | SUE: 0.01 | # QB: 0
Revenue Correlation: 75.95 | Revenue CAGR: 14.35% | SUE: 0.12 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.20 | Chg30d=-1.43% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-12-31): EPS=0.22 | Chg30d=+7.06% | Revisions=+25% | Analysts=1
EPS current Year (2027-03-31): EPS=0.98 | Chg30d=+5.08% | Revisions=+25% | GrowthEPS=+27.2% | GrowthRev=+250.3%
EPS next Year (2028-03-31): EPS=0.98 | Chg30d=+2.64% | Revisions=+25% | GrowthEPS=-0.6% | GrowthRev=+0.2%